Glepaglutide is under clinical development by Zealand Pharma and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Glepaglutide’s likelihood of approval (LoA) and phase transition for Short Bowel Syndrome took place on 03 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Glepaglutide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Glepaglutide (ZP-1848) is under development for the treatment of short bowel syndrome (SBS). ZP1848 is a long acting SIP-modified glucagon-like peptide-2 (GLP-2) analogue. It is administered as a solution through subcutaneous route. It is developed based on SIP technology. The SIP-technology is a protein modification technology. It was also under development for the treatment of Crohn’s disease.
Zealand Pharma overview
Zealand Pharma (Zealand) is a biotechnology company. It discovers, designs and develops peptide-based medicines that target specialty diseases. The company’s product portfolio comprises glepaglutide which is a long-acting GLP-2 analog in development for the treatment of short bowel syndrome and dasiglucagon is used against type 1 diabetes and congenital hyperinsulinism. It also offers GLP1-GLU which is used against several cardio-metabolic diseases such as heart disease, ischemic stroke and liver diseases. Zealand conducts research and development and in-licensing programs. It has operations in Denmark and the US. ealand is headquartered in Soeborg, Denmark.
Quick View Glepaglutide LOA Data
|Highest Development Stage|